Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved

Metagenomi Therapeutics, Inc.

Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.
Cash and equivalents $271.2M at Dec 31, 2023; plus $81.1M net IPO proceeds in Feb 2024.
Hemophilia A program achieved NHP proof of concept; development candidate nomination expected mid-2024.
Demonstrated CAST system for >10,000 bp targeted integrations and SMART base editors as small as 623 amino acids.
Cash runway supports 2 INDs and 2 additional development candidate nominations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Metagenomi, Inc. announced its financial results for the year ended December 31, 2023 and additional business updates.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.